3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
7
Active not recruiting
4
Unknown
1
Terminated
1
Suspended
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
3
Sarcoma
3
Head & Neck
3
Genitourinary
3
Dermatologic
2
CNS
2
Breast
2
Other solid neoplasm
1
Gynecologic
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Interventions
Paclitaxel
69
Carboplatin
66
Cisplatin
36
pembrolizumab
34
Gemcitabine
24
liposomal doxorubicin
23
Cyclophosphamide
23
Topotecan
22
Bevacizumab
20
Taxes
14
Docetaxel
13
niraparib
12
Nivolumab
12
olaparib
10
fludarabine
10
Doxorubicin
9
Surveys and Questionnaires
8
Radiotherapy
8
Oxaliplatin
8
aldesleukin
7
Filgrastim
7
rucaparib
6
oregovomab
6
fludarabine phosphate
6
durvalumab
6
avelumab
6
Interleukin-2
6
Hyperthermic Intraperitoneal Chemotherapy
6
Fluorodeoxyglucose F18
6
Cytoreduction Surgical Procedures
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
X-Rays
×
Gynecologic
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled